Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma
NCT02213926Phase 2Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Mar 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by Acerta Pharma. Primary endpoint: Overall Response Rate. Started Mar 2015; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02213926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213926.